Resources > Technologies Advancing Cell Therapy

Technologies Advancing Cell Therapy

All cell therapy development, either autologous or allogeneic, is underpinned by an understanding of the therapeutic or regenerative potential of an individual or combination of cell type(s), acting as an agent to address a specific indication or disease area with high unmet clinical need.

The first step in developing a cell therapy product is the identification and characterization of cells to ascertain their value in the context of a target indication or disease area. Despite nearly every cell in the human body contains the same genetic makeup, this remains a challenge due to each tissue and cell type’s unique way of organizing, accessing information, and understanding this content through differences in chromatin structure, epigenetic modification, gene activation and regulation, as well as other contextual cues.

The role of technologies in advancing cell therapy development is to both decipher this cellular information, mapping out the genomic, epigenomic, transcriptomic and proteomic landscapes of cells at an unprecedented scale and resolution, and leverage it in order to master the generation, maintenance and manipulation of clinically valuable cell types. Preferably through standardized and scalable cell sources and bioprocessing protocols, whilst also enhancing their therapeutic traits through biological modifications.

The last two decades have seen an exponential rise in the availability of such cellular data with numerous international research consortia deploying sequencing technologies, such as the Human Genome Project (Whole Genome Sequencing), the FANTOM project (CAGE-seq) and the ENCODE project (ChIP-seq), as well as the Human Cell Atlas projects’ use of single-cell RNA sequencing which has led to the discovery of previously unknown cell types and cellular heterogeneity (e.g. neuronal diversification and heterogeneity in the kidney).

View all resources 

Technologies Advancing Cell Therapy

Here we discuss the novel technologies and approaches leveraging biological data to underpin and advance the future development of cell (and gene) therapies. In particular, focusing on cellular and in vivo reprogramming innovation for the derivation and maintenance of clinically valuable cell types, such as MOGRIFY® and epiMOGRIFY™, as well as engineering of therapeutic cells to enhance efficacy, safety and scalability.

Application Note
The Potential of Pluripotent Stem Cells for 'Off-the-Shelf' Cell Therapy
2021   |   Alessandra de Riva, Eirini Koutsouraki
Human pluripotent stem cells (PSC) are characterized by their undifferentiated status, infinite self-renewal capacity, and ability to differentiate into any cell type in the body. These characteristics make them an ap...
Big data and cell therapy development: the pharmaphorum podcast
2021   |   Darrin M Disley
In this episode of the pharmaphorum podcast, Mogrify CEO Dr Darrin M Disley OBE speaks to web editor Catherine Longworth about his c...
Panel Discussion: iPSC expansion and differentiation
2020   |   RegMedNet
The creation of induced pluripotent stem cells (iPSCs) revolutionized the regenerative medicine field in 2006 when Shinya Yamanaka created his famous pluripotency cocktail of four factors. For the first time the world...
ISMB 2020 | Mogrify: A computational framework to convert between cell types
2020   |   Kalaivani Raju
Intelligent Systems for Molecular Biology (ISMB) brings together scientists from computer science, molecular biology, mathematics, statistics and related fields, and provides an intense multidisciplinary forum for dis...
Cell Therapy Manufacturing: Addressing the growing pains in cell therapy manufacturing
2020   |   Alessandra de Riva
With a number of therapeutic products finally on the market and several in ongoing clinical trials, cell therapy is gradually taking center stage in immuno-oncology. Developmental focus...
Application Note
Using big data approaches to develop cell therapies
2020   |   Owen Rackham
For decades the approach in cell biology has remained relatively unchanged. We isolate cells and with our confined knowledge of their endogenous conditions, begin to experiment until we can sustain them in vitro. Once...
Application Note
Computational Tools for Accelerating Regenerative Medicine
2020   |   Aida Moreno-Moral
Cell therapy has arisen as a leading approach to tackle tissue regeneration. It involves the direct transplantation of cells to compensate for those lost. In some cases, it is possible to extract healthy cells of inte...
10 Considerations for Enhancing Your iPSC Processing Pipeline
2020   |   RegMedNet
What are induced pluripotent stem cells (iPSCs)? iPSCs are derived from somatic cells that have been reprogrammed back into an embryonic-like pluripotent state. iPSCs offer an ev...
Application Note
Computational Algorithms and Large-Scale Data for CAR T Cell Therapy Resistance
2020   |   Raul Elguela, Aida Moreno-Moral and Rodrigo Santos
Chimeric antigen receptor T (CAR T) cells have become an important and novel therapy for patients with B cell malignancies, mainly due to recent advances in gene, protein, and cell engineering. However, the success of...
Application Note
Biology 3.0: The Single-Cell (R)evolution
2019   |   Vicki Moignard
Understanding how cells make choices is one of the great challenges in biology. Whether it is the first cell divisions of embryonic development or activation in response to an immune stimulus, modern medicine has a gr...